In a significant expansion for Texas' pharmaceutical manufacturing capacity, Governor Greg Abbott has recently unveiled plans for Eli Lilly and Company to construct a new active pharmaceutical ingredient (API) manufacturing facility in Harris County. According to a statement obtained by the Office of the Texas Governor, the project will span roughly 1 million square feet and is expected to exceed $6.5 billion in investment while creating upwards of 600 new positions.
Boosting Texas' role in the domestic production of next-generation small molecule synthetic medicines, the initiative has latched onto a $5.5 million Texas Enterprise Fund (TEF) grant, and has garnered approval under the state's Jobs, Energy, Technology, and Innovation (JETI) program. In the governor's own words, "Texas is the best state in America for doing business." The facility signifies a stride towards self-sufficiency, aiming to diminish reliance on international production lines. Running parallel to his rationale, "Texas is doing its part to bring manufacturing capacity back to America and expanding biomedical manufacturing right here in our great state," Abbott told the Office of the Texas Governor.
Lilly's investment is considered unparalleled for the region, signaling a surge in Harris County's aspiration to be a beacon for life sciences. "Lilly’s decision to invest more than $6.5 billion in Harris County is a powerful testament to the strength of our community," Harris County Commissioner Rodney Ellis told the Office of the Texas Governor. Ellis points out the anticipated benefits, from fostering economic growth to creating equitable job prospects that sustain working families in Harris County.
To echo the sentiment, David A. Ricks, Lilly's Chair and CEO, emphasizes the investment's larger scope, "Our new U.S. manufacturing facilities are more than just an investment in infrastructure —they're a commitment to American innovation, onshoring jobs, economic growth, and public health," as per the Office of the Texas Governor's release. Ricks asserts that amplifying in-house production strengthens the supply chain and energizes the pace of delivering critical medications to those in need.
This monumental move is also perceived as a boon for the local education sector. Proudly welcoming Lilly, Sheldon ISD Superintendent Dr. Demetrius McCall avers that the collaboration stands as a bastion of joint focus on novelty, scholarship, and opportunity. "Together, we will empower our students with the skills and experiences they need to thrive in a global workforce," McCall shared with the Office of the Texas Governor.
Lastly, the Greater Houston Partnership President and CEO, Steve Kean, hailed the project as a transformative epoch for Houston's life sciences industry. "The Lilly project represents one of the largest for-profit life sciences investments in Texas history and is a powerful endorsement of Houston’s growing position as a global hub for innovation, advanced manufacturing, and biomedical excellence," Kean pointed out in the same press release. According to Kean, this win reflects the strategic efforts from diverse partners across sectors to construct the talent and infrastructure necessary to allure top-tier enterprises such as Lilly to Houston.
